Abstract:<p>Dysregulation of histone methyltransferase enhancer of zeste homolog 2 (EZH2) has been implicated in the pathogenesis of many cancers. However, the role of EZH2 in peritoneal fibrosis remains unknown. We investigated EZH2 expression in peritoneal dialysis (PD) patients and assessed its role in peritoneal fibrosis in cultured human peritoneal mesothelial cells (HPMCs) and murine models of peritoneal fibrosis induced by chlorhexidine gluconate (CG) or high glucose peritoneal dialysis fluid (PDF) by using 3‐deazaneplanocin A (3‐DZNeP), and EZH2 conditional knockout mice. An abundance of EZH2 was detected in the peritoneum of patients with PD associated peritonitis and the dialysis effluent of long‐term PD patients, which was positively correlated with expression of transforming growth factor‐β1 (TGF‐β1), vascular endothelial growth factor, and interleukin‐6. EZH2 was found highly expressed in the peritoneum of mice following injury by CG or PDF. In both mouse models, treatment with 3‐DZNeP attenuated peritoneal fibrosis and inhibited activation of several pro‐fibrotic signaling pathways, including TGF‐β1/Smad3, Notch1, epidermal growth factor receptor and Src. EZH2 inhibition also inhibited STAT3 and nuclear factor‐κB phosphorylation, and reduced lymphocyte and macrophage infiltration and angiogenesis in the injured peritoneum. 3‐DZNeP effectively improved high glucose PDF‐associated peritoneal dysfunction by decreasing the dialysate‐to‐plasma (D/P) ratio of BUN and increasing the ratio of dialysate glucose at 2 h after PDF injection to initial dialysate glucose. Moreover, delayed administration of 3‐DZNeP inhibited peritoneal fibrosis progression, reversed established peritoneal fibrosis and reduced expression of tissue inhibitor of metalloproteinase 2 (TIMP2), and matrix metalloproteinase‐2 and ‐9. Finally, EZH2‐KO mice exhibited less peritoneal fibrosis than EZH2‐WT mice. In HPMCs, treatment with EZH2 siRNA or 3‐DZNeP suppressed TGF‐β1‐induced upregulation of α‐SMA and Collagen I and preserved E‐cadherin. These results indicate that EZH2 is a key epigenetic regulator that promotes peritoneal fibrosis. Targeting EZH2 may have the potential to prevent and treat peritoneal fibrosis.</p><p>This article is protected by copyright. All rights reserved.</p>

Transforming growth factor β-induced peritoneal fibrosis is mouse strain dependent.

Prolonged peritoneal gene expression using a helper-dependent adenovirus.

Genetic strain differences in the development of peritoneal fibroproliferative processes in mice

Effects of Short Hairpin RNAs on TGF-β1 Expression and Ultrastructure in HPMCs Induced by Peritoneal Dialysis Solution

Mice Overexpressing Latent Tgf-Beta 1 Are Protected Against Renal Fibrosis In Obstructive Kidney Disease

Mice overexpressing latent TGF-β1 are protected against renal fibrosis in obstructive kidney disease

TGF2 and TGF3 isoforms drive fibrotic disease pathogenesis

Peritoneal Morphological and Functional Changes Associated with Platelet-Derived Growth Factor B

[The Role of TGF-beta1/Smads in the Development of Peritoneal Fibrosis Induced by High Glucose Peritoneal Dialysate and LPS].

Transforming Growth Factor Β1 Induces Epithelial–mesenchymal Transition by Activating the Jnk–SMAD3 Pathway in Rat Peritoneal Mesothelial Cells

Beta-Catenin Participates in Dialysate-Induced Peritoneal Fibrosis Via Enhanced Peritoneal Cell Epithelialto-Mesenchymal Transition

TGF{beta} drives fibrotic remodeling via modulation of homeostatic and pathological fibroblast populations in a murine model of pulmonary fibrosis

Matrix Metalloproteinase 9 is Associated with Peritoneal Membrane Solute Transport and Induces Angiogenesis Through Β-Catenin Signaling.

WNT Signaling is Required for Peritoneal Membrane Angiogenesis.

TGF-β, Smad3 and the process of progressive fibrosis

A Maladaptive Role for EP4 Receptors in Mouse Mesangial Cells.

Abstract Tu061: Pericyte-mediated perivascular fibrosis in the pressure-overloaded heart is dependent on TGF-β signaling and is restrained by ITGB1.

MicroRNA-302c Modulates Peritoneal Dialysis-Associated Fibrosis by Targeting Connective Tissue Growth Factor

Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis

Murine Precision-Cut Kidney Slices as an ex vivo Model to Evaluate the Role of Transforming Growth Factor-β1 Signaling in the Onset of Renal Fibrosis

SPHK1/S1P/S1PR Pathway Promotes the Progression of Peritoneal Fibrosis by Mesothelial-Mesenchymal Transition